What is Neuroprotection Market?
Neuroprotection refers to a disease-modifying event that aims to protect the nervous system from injury and damage, especially in people who sustain an injury or develop a health condition that has neurological effects. The factors such as increased incidences of CNS disorders and increasing demand for more target-specific drug treatment for neurodegenerative diseases are driving the global neuroprotection market.
The market study is being classified by Type (Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs), Metal Ion Chelators, Stimulants and Others), by Application (Prevention and Treatment) and major geographies with country level break-up.
Daiichi Sankyo Company (Japan), Eli Lilly and Company (United States), Allergan, Inc. (Ireland), Dr. Reddy’s Laboratories (India), Teva Pharmaceutical (Israel), Novartis International AG (Switzerland), AstraZeneca plc (United Kingdom), Astrocyte Pharmaceuticals (United States), Roche Holding AG (Switzerland) and Biogen Inc. (United States) are some of the key players profiled in the study.
There are various companies that are operating in the new geographical regions by adopting various market growth initiatives such as mergers & acquisitions, expansions, investments, and others. There are various new market players are entering the market to capture market growth opportunities. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Neuroprotection market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Neuroprotection market by Type, Application and Region.
On the basis of geography, the market of Neuroprotection has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Neurological Disorders
- Limitations of Current Pharmacological Treatments for Neurogenerative Diseases
- Advancements in the Medical Science
- High Cost of Research and Development Investment
- Stringent Government Rules and Regulations
Key Target AudienceNeuroprotection Products Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase